BIO Deutschland elects new board at 22nd Annual General Meeting
The BIO Deutschland elected a new board for the next two years during its 22nd Annual General Meeting in Berlin 17 September.
The ten members of the BIO Deutschland board represent different areas of the innovative biotechnology industry.
The following were re-elected:
- Prof. Dr. Kathrin Sabine Adlkofer, Chief Executive Officer and founder of Cellbox Solutions GmbH, Lübeck
- Norbert Hentschel, Commercial Managing Director of Miltenyi Biotec B.V. & Co. KG, Bergisch-Gladbach
- Dr. Klaus Maleck, Chief Financial Officer, ITM SE, Munich
- Oliver Schacht, PhD, Oliver Schacht, PhD, Managing Director of Life Science Nord Management GmbH, Hamburg
- Roland Sackers, Chief Financial Officer and Managing Director of QIAGEN N.V., Hilden
- Dr. Sylvia Wojczewski, Chief Executive Officer of BioSpring GmbH, Frankfurt am Main
Newly elected to the Executive Board:
- Dr. Hubert Birner, Managing Partner of TVM Capital GmbH and TVM Life Science Management GmbH, Munich
- Peter Mitterhofer, General Manager Germany of BioNTech Europe GmbH, Mainz, Berlin
- Dr. Dominik Schumacher, CEO of Tubulis GmbH, Planegg
- Raffael Wohlgensinger, CEO of Formo Bio GmbH, Berlin, Frankfurt am Main
Following the general meeting, the new Executive Board unanimously elected Roland Sackers as its new Chairman. Norbert Hentschel was re-elected as Treasurer.
At the general meeting, the association's management also presented a comprehensive report and briefly highlighted the main activities of the past twelve months.
